Search | Clinical Trials Finder

Conditions: Sinusitis, Cystic Fibrosis
Interventions: Pulmozyme single use ampule, placebo; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 12 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Respiratory Syncytial Virus
Interventions: mRNA-1345, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 349 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 47
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Banning, California + 41 more

Conditions: Obstetric Labour, Premature
Interventions: Retosiban, Atosiban, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 10 Weeks to 20 Weeks
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Park Ridge, Illinois • Galveston, Texas

Conditions: Post-operative Cognitive Decline, Post-operative Delirium
Interventions: Aspart insulin, Normal saline, Intranasal mucosal atomizer device; Drug · Device
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 65 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Atherosclerotic Cardiovascular Disease
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: University of Oxford; Other
Eligibility: 40 Years and older
Enrollment: 16,124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2049
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Phase 1 First-in-human Study Involving Healthy Subjects
Interventions: TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH); Drug · Biological
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Primary Hyperoxaluria Type 1 (PH1)
Interventions: Placebo, Lumasiran; Drug
Lead sponsor: Alnylam Pharmaceuticals; Industry
Eligibility: 6 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 5
States / cities: San Diego, California • Jacksonville, Florida • Rochester, Minnesota + 2 more

Conditions: Anesthesia, Local, Shoulder Surgery
Interventions: saline, Dexamethasone, ropivacaine, Bupivacaine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: SARS-CoV-2
Interventions: mRNA-1273, mRNA-1283, Placebo; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years to 64 Years
Enrollment: 30,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 150
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 127 more

Conditions: Suicide, Attempted
Interventions: Ketamine Hydrochloride, Saline, CAMS Therapy; Drug · Behavioral
Lead sponsor: Tatiana Falcone, MD; Other
Eligibility: 14 Years to 30 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: HIV Positive, Anal Condylomata, Anal Warts, HIV Infections
Interventions: Saline, Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Clostridoides Difficile Associated Disease
Interventions: C. difficile vaccine (previously studied formulation)., C. difficile vaccine formulation 1., C. difficile vaccine formulation 2., C. difficile vaccine formulation 3., Saline Placebo.; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years and older
Enrollment: 936 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2031
U.S. locations: 23
States / cities: Phoenix, Arizona • Anaheim, California • Doral, Florida + 17 more

Conditions: Healthy Volunteers
Interventions: AV-1, Placebo; Drug
Lead sponsor: AbViro LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: HIV Infections
Interventions: HIV-MAG vaccine, IL-12 pDNA adjuvant, VSV HIV gag vaccine, Placebo, Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device; Biological · Device
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: New York, New York • Rochester, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Latrodectism
Interventions: Analatro, Saline; Drug
Lead sponsor: Instituto Bioclon S.A. de C.V.; Industry
Eligibility: 10 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 16
States / cities: Phoenix, Arizona • Davis, California • Fresno, California + 11 more

Conditions: Pain, Postoperative
Interventions: ropivacaine; Drug
Lead sponsor: Liberman, Eric, D.O.; Individual
Eligibility: 18 Years and older · Female only
Enrollment: 220 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Livingston, New Jersey

Conditions: NAFLD, Diabetes Mellitus, Type 2, Hypertriglyceridemia, Fatty Liver, Nonalcoholic
Interventions: Placebo, ISIS 703802 40 mg, ISIS 703802 80 mg, ISIS 703802 20 mg; Drug
Lead sponsor: Akcea Therapeutics; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 38
States / cities: Chandler, Arizona • Fountain Hills, Arizona • Glendale, Arizona + 30 more

Conditions: Chemotherapy-induced Neuropathic Pain, Chemotherapy-induced Peripheral Neuropathy
Interventions: Tetrodotoxin, Placebo; Drug
Lead sponsor: Wex Pharmaceuticals Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 15
States / cities: Santa Ana, California • Santa Rosa, California • Port Charlotte, Florida + 11 more

Conditions: Anesthesia
Interventions: Caffeine, Placebo Control; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 25 Years to 40 Years · Male only
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infections, Urinary Tract
Interventions: GSK2251052, imipenem-cilastatin, Placebo; Drug · Other
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 4
States / cities: Los Angeles, California • Council Bluffs, Iowa • Topeka, Kansas + 1 more

Conditions: Bacterial Disease Carrier, Cystic Fibrosis
Interventions: Placebo, WRAIR-PAM-CF1; Other · Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 19
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 15 more

Conditions: Pre-eclampsia
Interventions: Anti-digoxin antibody (FAB fragment), sodium chloride; Drug · Other
Lead sponsor: BTG International Inc.; Other
Eligibility: Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Mobile, Alabama • Phoenix, Arizona • Orlando, Florida + 5 more

Conditions: ASCVD, Elevated Cholesterol
Interventions: Inclisiran Sodium, Placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 1,561 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 145
States / cities: Birmingham, Alabama • Foley, Alabama • Huntsville, Alabama + 110 more

Conditions: Acute Myocardial Infarction, STEMI
Interventions: FDY-5301, Placebo; Drug · Other
Lead sponsor: Faraday Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Minneapolis, Minnesota • The Bronx, New York

Search by objective public record fields.

Pulmozyme in Cystic Fibrosis With Sinusitis

A Study of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus

Follow up Study to Assess Long Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

Cardiac Surgery Neuroprotection Study in Elders

A Randomized Trial Assessing the Effects of Inclisiran on Clinical Outcomes Among People With Cardiovascular Disease

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1

The Effect of Dexamethasone on the Duration of Interscalene Nerve Blocks With Ropivacaine or Bupivacaine

A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19)

Ketamine Treatment of Youth Suicide Attempters

The Effect of HPV Vaccination on Recurrence Rates in HIV Patients With Condylomata

To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

Evaluating the Safety of and Immune Response to HIV-MAG DNA Vaccine With or Without Plasmid IL-12 Adjuvant Delivered Intramuscularly Via Electroporation Followed by VSV-gag HIV Vaccine Boost in Healthy, HIV-Uninfected Adults

Black Widow Spider Antivenin for Patients With Systemic Latrodectism

Efficacy of Transversus Abdominis Plane Block Versus Local Injection of Pain Medication

Study of ISIS 703802 in Participants With Hypertriglyceridemia, Type 2 Diabetes Mellitus, and Nonalcoholic Fatty Liver Disease

A Randomized, Double-Blind, Placebo Controlled, Multicenter, Efficacy and Safety Trial of Single Cycle Tetrodotoxin in the Treatment of Chemotherapy Induced Neuropathic Pain

A Study to Determine if Caffeine Accelerates Emergence From Anesthesia

GSK2251052 in Complicated Urinary Tract Infection

A Phase 1b/2 Trial of the Safety and Microbiological Activity of Bacteriophage Therapy in Cystic Fibrosis Subjects Colonized With Pseudomonas Aeruginosa

Efficacy Study of Digibind for Treatment of Severe Preeclampsia

Inclisiran for Participants With Atherosclerotic Cardiovascular Disease and Elevated Low-density Lipoprotein Cholesterol

A Study of Acute Myocardial Infarction Using FDY-5301